Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. - Test2 - elhamkhani - TriplyDB

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

http://www.wikidata.org/entity/Q40015224

about

Targeted therapies in sarcomas: challenging the challenge Targeted immunotherapy for pediatric solid tumors Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation Children's Oncology Group's 2013 blueprint for research: bone tumors Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data.Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: a report from the Children's Oncology Group.Immune-based therapeutics for pediatric cancer.Immunotherapy of childhood cancer: from biologic understanding to clinical application.Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Assessing cytotoxic treatment effects in preclinical tumor xenograft models.The human IGF1R IRES likely operates through a Shine-Dalgarno-like interaction with the G961 loop (E-site) of the 18S rRNA and is kinetically modulated by a naturally polymorphic polyU loop.Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program.The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program.Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507.Treatment of Bone Tumors Clinicopathological characteristics and treatment outcomes of Chinese patients with genitourinary embryonal rhabdomyosarcoma.Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.Molecular profiling of childhood cancer: Biomarkers and novel therapies Statistical inference for tumor growth inhibition T/C ratio.Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines The Current and Future Therapies for Human Osteosarcoma.The application of radiation therapy to the Pediatric Preclinical Testing Program (PPTP): results of a pilot study in rhabdomyosarcoma.Recent advances in the molecular pathogenesis of Ewing's sarcoma.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group.Insulin-like growth factor: current concepts and new developments in cancer therapy.The role of IGF-1R in pediatric malignancies.Genetically modified T cells targeting interleukin-11 receptor α-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center.The T-box transcription factor 3 is a promising biomarker and a key regulator of the oncogenic phenotype of a diverse range of sarcoma subtypes

P2860

Q21285014-16ADF609-FFAE-4E58-BC90-BBC8BE1BDA94 Q26747703-CEEB2FFB-EB45-463C-9C0B-D316B55714DF Q26784048-7182B5E9-2BDD-4F34-B59B-2DBE14600F06 Q27027664-46C922E5-EE54-4051-9686-87DB703130D9 Q30540343-A5A63774-8458-49BE-AD0D-8EB3D5A77BE5 Q33500359-B934528B-254E-4C1F-A735-0A2FCF6E8484 Q33520467-8119F628-4DB0-4A6D-881E-6BBCD1BA7B4D Q33559559-8F2C6596-58DB-423B-8B6D-F1C128D0386C Q33604121-1474F1DC-E208-41E7-BD46-4BE0F657EB64 Q33752982-9A96782F-0DCC-49FE-88E4-48C629A73B1A Q33925323-EB2007BF-F5D5-461C-84E2-55C9F7ADDE8D Q34110523-733CCF9E-B352-4644-A31E-CD4D2F99D381 Q34300641-62F2D059-3D70-4659-A8BE-13E7311E9805 Q34380167-41B47B97-9C45-4ED6-B8E9-8D062C1FE4DC Q34391968-6AF56781-7201-4B80-A835-F438FC47E2A6 Q34414710-69835212-A4EC-42B4-B25A-005A8ECA8CD5 Q34414730-7EBD1ECF-A582-4D85-AB67-1EDBC9449FA5 Q34532397-CAEE238C-3CA6-45DE-8BA9-633A739043D1 Q34683782-1DCBA8FE-8C66-4B00-AE93-DCE0C29518DF Q34728942-C2D9E678-77D1-4EE8-888D-3157DF662FED Q35013284-26E5C738-1D23-4D94-A1B9-03E8DFEB60F7 Q35194644-E68ECE4C-7322-4B27-9DB7-AD52092A87FF Q35627019-0AF90047-1AF7-4D25-BF4B-C31AA9E386C8 Q35740708-3CECA9B1-EA15-4915-AFDE-B0ED06AE11AF Q35762410-C0AFE4F0-ED1B-4A27-81AB-D86C392BA7C0 Q35791105-494E5FED-BE7A-418E-A71B-396F095E8AD3 Q36170917-C98C3381-6BA2-4662-B893-42995E224780 Q36250783-C7E6BD9C-29E8-43B5-A27A-357A31A88473 Q36344897-56DAAB50-5F7E-4117-A863-595B853C5333 Q36438319-83FDAA0E-85C5-44D2-B54A-B96F15B51E14 Q36514299-D2216D52-AFA4-46ED-B7ED-759D302845B2 Q36522856-72D2DA06-EF7E-477B-AD9B-78804DF3FA6B Q36562720-E6FE4AFB-8689-4864-8FFA-B3210DFAACAE Q36888962-2819CC18-EC6D-499F-929E-4DA0D65029E6 Q36907188-37C9C72F-E578-49CD-A420-30FD5DE8E034 Q37047067-097792DC-25E4-4B73-9D31-5A6D834C3C12 Q37290912-12EF533E-BBA3-4FF9-9766-4C56169623F7 Q37324303-0CB307C7-ABFB-4F3A-ADBF-D6106F5166E1 Q37425429-93EFF000-A089-43DE-9340-405D9B799305 Q37499273-0072EB55-470D-47F6-9BD0-A42D85E74386

P2860

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

http://www.wikidata.org/entity/Q40015224

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Initial testing (stage 1) of a ...... c preclinical testing program.

@en

type

label

Initial testing (stage 1) of a ...... c preclinical testing program.

@en

prefLabel

Initial testing (stage 1) of a ...... c preclinical testing program.

@en

P1433

Q40015224-8D844D98-B235-48DE-B174-5391CD43F586

P1476

Q40015224-C85C380F-89ED-4C19-AD4E-3F6B7C20A8D8

P2093

Q40015224-0170C768-F4B1-4707-8A88-E73BF949204C

Q40015224-02FAD048-40A8-4CFD-A3A8-EB9099BB7F67

Q40015224-0D5D5A35-A860-465A-ACA6-DE545F764C89

Q40015224-1D5FFDFF-9E64-4468-8AFB-1212979BAE4C

Q40015224-203DE7DB-7CAA-4A83-A989-85989637FF79

Q40015224-43B2BA42-2AF5-4EE5-9C31-6D1A51C5C87B

Q40015224-43D5DE93-713C-4112-9E25-9F3011C8D69C

Q40015224-4E8B4BBE-4E89-4565-A257-385325C2981D

Q40015224-60C6B0FB-9998-4905-9D31-C9724B7E4D93

Q40015224-C5C53A0E-A6A9-4124-B4D3-D22F7D34FD69

P2860

Q40015224-432E3485-0578-4A6A-AAC4-AA73273C5C7E

Q40015224-E22BE85C-8286-45EE-922E-5C725A895F3D

P304

Q40015224-62CCE7FB-DF7B-4549-9720-D2CCA57AD928

P31

Q40015224-3B29A6E7-2AAA-4EA8-B77B-8705D1A11B41

P356

Q40015224-625AAA14-E35D-4DE1-92C5-279B5916811F

P433

Q40015224-7F90059D-5164-42DD-A50D-6F170EB52B3B

P478

Q40015224-5912AD57-E65D-4851-9D23-803D06A3D0A5

P577

Q40015224-151816E3-8FD4-44A4-A5B2-49BB38F294A2

P698

Q40015224-B926C711-34E8-4D2E-9A7C-718EF849D0A9

P921

Q40015224-E9060005-CB3C-4F12-9802-5DC7F10C98AF

P356

P1433

Pediatric Blood & Cancer

P1476

Initial testing (stage 1) of a ...... c preclinical testing program.

@en

P2093

C Patrick Reynolds

http://www.w3.org/2001/XMLSchema#string

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

Christopher L Morton

http://www.w3.org/2001/XMLSchema#string

E Anders Kolb

http://www.w3.org/2001/XMLSchema#string

Hernan Carol

http://www.w3.org/2001/XMLSchema#string

John M Maris

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Richard Gorlick

http://www.w3.org/2001/XMLSchema#string

Richard Lock

http://www.w3.org/2001/XMLSchema#string

P2860

Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

P304

1190-1197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.21450

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18260118

http://www.w3.org/2001/XMLSchema#string

P921